Obinutuzumab (Gazyva) improved overall response and had acceptable toxicity compared with rituximab (Rituxan) in patients with relapsed indolent non-Hodgkin lymphoma (iNHL),
Journal of Clinical Oncology Publishes GAUSS Trial Data
Obinutuzumab (Gazyva) improved overall response and had acceptable toxicity compared with rituximab (Rituxan) in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to the final results from the GAUSS study published in the Journal of Clinical Oncology. However, the higher response did not result in an improvement in progression-free survival (PFS), leaving the role of obinutuzumab unclear in this setting.
